Top

Published in:

01-12-2024 | Kidney Cancer | Topic Paper

A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma

Authors: Osbert Zalay, Prateek Mehra, Ian Pereira, Julia Malone, Shawn Malone

Published in: World Journal of Urology | Issue 1/2024

Abstract

Renal cell carcinoma (RCC) is an uncommon malignancy whose incidence has been increasing over the past few decades, posing treatment challenges for elderly or infirm patients who are not surgical candidates. Stereotactic ablative radiotherapy (SABR) has emerged as a promising non-invasive treatment modality for RCC. The high dose-per-fraction used in SABR overcomes some of the mechanisms of radioresistance that has hindered the effective treatment of RCC with conventional radiotherapy. For primary RCC, local control rates for SABR exceed 90%, with typically minimal grade 3 or higher toxicities, offering a viable alternative for inoperable patients and those not eligible for or unable to tolerate radiofrequency or cryotherapy ablation. SABR can also be used in patients with a solitary kidney as a strategy for renal preservation to avoid need for dialysis. Given its excellent local control rates, low toxicity and preservation of renal function, SABR offers an attractive alternative to more invasive modalities for treatment of localized RCC.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30(5):706–720PubMedCrossRef

Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335(12):865–875PubMedCrossRef

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249CrossRef

Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH (2019) Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer 17(1):46-57.e5PubMedCrossRef

Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167(1):57–60PubMedCrossRef

Campi R, Rebez G, Klatte T, Roussel E, Ouizad I, Ingels A et al (2023) Effect of smoking, hypertension and lifestyle factors on kidney cancer - perspectives for prevention and screening programmes. Nat Rev Urol 20(11):669–681PubMedCrossRef

King SC, Pollack LA, Li J, King JB, Master VA (2014) Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol 191(6):1665–1670PubMedPubMedCentralCrossRef

Deschavanne PJ, Fertil B (1996) A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 34(1):251–266PubMedCrossRef

Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in Vitro and in Vivo in human renal cell carcinoma xenografts. Cancer 80(S12):2519–2528PubMedCrossRef

10.

Leksell L (1951) The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102(4):316–319PubMed

11.

Takeuchi H, Yoshida M, Kubota T, Ishii H, Sato K, Handa Y et al (2003) Frameless stereotactic radiosurgery with mobile CT, mask immobilization and micro-multileaf collimators. Minim Invasive Neurosurg 46(2):82–85PubMedCrossRef

12.

Meeks SL, Bova FJ, Wagner TH, Buatti JM, Friedman WA, Foote KD (2000) Image localization for frameless stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 46(5):1291–1299PubMedCrossRef

13.

Kuo JS, Yu C, Petrovich Z, Apuzzo MLJ (2008) The Cyberknife stereotactic radiosurgery system: description, installation, and an initial evaluation of use and functionality. Neurosurgery 62:SHCCrossRef

14.

Qian G, Lowry J, Silverman P, Grosman I, Makara D, Lederman G (2003) Stereotactic extra-cranial radiosurgery for renal cell carcinoma. Int J Radiat Oncol Biol Phys 57(2):S283CrossRef

15.

Zoumpourlis P, Genovese G, Tannir NM, Msaouel P (2021) Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn’t, and what the future holds. Clin Genitourin Cancer 19(2):103–116PubMedCrossRef

16.

Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, Teh BS et al (2017) Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 14(9):549–563PubMedCrossRef

17.

NCCN (2023) NCCN Guidelines Version 1.2024 Kidney Cancer. Available from: https://www.nccn.org/guidelines/guidelines-detail

18.

Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A et al (2016) Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol 12(5):637–645PubMedCrossRef

19.

Psutka SP, Heidenreich M, Boorjian SA, Bailey GC, Cheville JC, Stewart-Merrill SB et al (2017) Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU Int 119(1):116–127PubMedCrossRef

20.

Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12(1):206–212PubMedCrossRef

21.

Ray S, Cheaib JG, Pierorazio PM (2020) Active surveillance for small renal masses. Rev Urol 22(1):9–16PubMedPubMedCentral

22.

Kunkle DA, Uzzo RG (2008) Cryoablation or radiofrequency ablation of the small renal mass. Cancer 113(10):2671–2680PubMedCrossRef

23.

Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A et al (2019) Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 76(2):244–251PubMedCrossRef

24.

Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM et al (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45(7):870–875PubMedCrossRef

25.

Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12):1508–1516PubMedCrossRef

26.

Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L et al (2019) The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus 5(6):958–969PubMedCrossRef

27.

Grubb WR, Ponsky L, Lo SS, Kharouta M, Traughber B, Sandstrom K et al (2021) Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 1(155):138–143CrossRef

28.

Siva S, Pham D, Gill S, Corcoran NM, Foroudi F (2012) A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 110(11 Pt B):E737–E743PubMed

29.

Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R et al (2015) Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 117(1):183–187PubMedCrossRef

30.

Staehler M, Bader M, Schlenker B, Casuscelli J, Karl A, Roosen A et al (2015) Single fraction radiosurgery for the treatment of renal tumors. J Urol 193(3):771–775PubMedCrossRef

31.

Teh B, Bloch C, Galli-Guevara M, Doh L, Richardson S, Chiang S et al (2007) The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 3(1):e6PubMedPubMedCentral

32.

Pham D, Thompson A, Kron T, Foroudi F, Kolsky MS, Devereux T et al (2014) Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys 90(5):1061–1068PubMedCrossRef

33.

Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH et al (2017) Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 120(5):623–630PubMedCrossRef

34.

Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS et al (2022) The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol 82(6):613–622PubMedCrossRef

35.

Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L et al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 124(5):934–942PubMedCrossRef

36.

Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L et al (2020) Stereotactic ablative radiotherapy for ≥T1b primary renal cell carcinoma: a report from the international radiosurgery oncology consortium for kidney (IROCK). Int J Radiat Oncol Biol Phys 108(4):941–949PubMedCrossRef

37.

Rabbani F, Herr HW, Almahmeed T, Russo P (2002) Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol 20(9):2370–2375PubMedCrossRef

38.

Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L et al (2019) Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK. J Urol 201(6):1097–1104PubMedCrossRef

39.

Paparel P, Bigot P, Matillon X, Bensalah K, Salomon L, Baumert H et al (2014) Local recurrence after radical nephrectomy for kidney cancer: management and prediction of outcomes. A multi-institutional study. J Surg Oncol 109(2):126–131PubMedCrossRef

40.

Liu Y, Zhang X, Ma H, Tian L, Mai L, Long W et al (2022) Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities. Cancer Med 11(23):4430–4439PubMedPubMedCentralCrossRef

41.

Mootha RK, Butler R, Laucirica R, Scardino PT, Lerner SP (1999) Renal cell carcinoma with an infrarenal vena caval tumor thrombus. Urology 54(3):561PubMedCrossRef

42.

Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I et al (2021) Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus—safety lead-in results of a Phase 2 trial. Int J Radiat Oncol Biol Phys 110(4):1135–1142PubMedPubMedCentralCrossRef

43.

Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA et al (2022) Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urol Oncol 40(4):166.e9-166.e13PubMedCrossRef

Title: A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma
Authors: Osbert Zalay
Prateek Mehra
Ian Pereira
Julia Malone
Shawn Malone
Publication date: 01-12-2024
Publisher: Springer Berlin Heidelberg
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Radiotherapy
Cryotherapy
Cryotherapy
Published in: World Journal of Urology / Issue 1/2024
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04731-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Evaluation of a novel circulation system for ureteroscopic laser lithotripsy in vitro

Glycolate oxidase-1 gene variants influence the risk of hyperoxaluria and renal stone development

Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy

PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions

Comparison of metabolic parameters between pure-uric acid and mixed-uric acid kidney stone formers

Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer